Abstract
A liquid chromatography-tandem mass spectrometry method was developed and validated for the quantification of KR-69232, a diacyltransferase 1 inhibitor, in rat plasma. KR-69232 in the concentration range of 0.004-4 µg/mL was linear. The intra-and inter-day precision and accuracy were acceptable (<20%). KR-69232 was stable under various storage and handling conditions. The method was applied successfully in a pharmacokinetic study of KR-69232 in rats.
Keywords:
DGAT-1 inhibitor; LC-MS/MS; method validation; pharmacokinetics.
Copyright © 2013 John Wiley & Sons, Ltd.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acetates / blood*
-
Acetates / chemistry
-
Acetates / pharmacokinetics
-
Animals
-
Benzimidazoles / blood*
-
Benzimidazoles / chemistry
-
Benzimidazoles / pharmacokinetics
-
Chromatography, High Pressure Liquid / methods*
-
Diacylglycerol O-Acyltransferase / antagonists & inhibitors*
-
Drug Stability
-
Enzyme Inhibitors / blood*
-
Enzyme Inhibitors / chemistry
-
Enzyme Inhibitors / pharmacokinetics
-
Rats
-
Rats, Sprague-Dawley
-
Reproducibility of Results
-
Tandem Mass Spectrometry / methods*
Substances
-
2-(4-(4-(5-(2-phenyl-5-(trifluoromethyl)oxazole-4-carboxamido)-1H-benzo(d)imidazol-2-yl)phenyl)cyclohexyl)acetic acid
-
Acetates
-
Benzimidazoles
-
Enzyme Inhibitors
-
Diacylglycerol O-Acyltransferase